Provided by Tiger Fintech (Singapore) Pte. Ltd.

Annexon, Inc.

1.68
+0.220015.07%
Pre-market: 1.680.00000.00%04:11 EDT
Volume:3.60M
Turnover:5.96M
Market Cap:184.31M
PE:-1.67
High:1.77
Open:1.42
Low:1.40
Close:1.46
Loading ...

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
17 Apr

Annexon Biosciences’ ANX005: Promising Phase III Results and Strategic Initiatives Drive Buy Rating

TIPRANKS
·
10 Apr

Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder

Benzinga
·
10 Apr

Annexon Cites 'Durable Benefit' of Tanruprubart in Guillain-Barre Syndrome Trial

MT Newswires Live
·
09 Apr

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

GlobeNewswire
·
09 Apr

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

GlobeNewswire
·
04 Apr

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
18 Mar

Annexon Biosciences: Promising Developments and Strategic Milestones Justify Buy Rating

TIPRANKS
·
08 Mar

Promising Developments in Annexon Biosciences’ Pipeline Drive Buy Rating

TIPRANKS
·
04 Mar

Promising Potential of Annexon Biosciences’ ANX1502 Drives Buy Rating Amid Positive Clinical Data

TIPRANKS
·
04 Mar

Annexon price target lowered to $20 from $30 at H.C. Wainwright

TIPRANKS
·
04 Mar

Annexon Price Target Maintained With a $16.00/Share by Needham

Dow Jones
·
04 Mar

Strategic Advancements and Financial Stability Drive Buy Rating for Annexon Biosciences

TIPRANKS
·
04 Mar

Wells Fargo Reaffirms Their Buy Rating on Annexon Biosciences (ANNX)

TIPRANKS
·
04 Mar

Annexon Biosciences Reports Strong Progress in 2024

TIPRANKS
·
04 Mar

Annexon Q4 EPS $(0.33) vs $(0.36) YoY

Benzinga
·
03 Mar

Annexon Biosciences Q4 Basic EPS USD -0.33

THOMSON REUTERS
·
03 Mar

Annexon Biosciences Q4 Operating Expenses USD 52.479 Million

THOMSON REUTERS
·
03 Mar

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

GlobeNewswire
·
03 Mar

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
27 Feb